haloperidol has been researched along with Anterior Horn Cell Disease in 2 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Excerpt | Relevance | Reference |
---|---|---|
" VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
"Frontotemporal lobar degeneration (FTLD) is the most common cause of early-onset dementia." | 1.36 | Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. ( Barcikowska, M; Blair, IP; Brooks, WS; Coupland, KG; Dobson-Stone, C; Halliday, GM; Karlström, H; Kwok, JB; Loy, CT; Luty, AA; Maruszak, A; Mather, KA; Panegyres, PK; Sachdev, PS; Schofield, PR; Sobow, T; Tchorzewska, J; Williams, KL; Zekanowski, C, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Luty, AA | 1 |
Kwok, JB | 1 |
Dobson-Stone, C | 1 |
Loy, CT | 1 |
Coupland, KG | 1 |
Karlström, H | 1 |
Sobow, T | 1 |
Tchorzewska, J | 1 |
Maruszak, A | 1 |
Barcikowska, M | 1 |
Panegyres, PK | 1 |
Zekanowski, C | 1 |
Brooks, WS | 1 |
Williams, KL | 1 |
Blair, IP | 1 |
Mather, KA | 1 |
Sachdev, PS | 1 |
Halliday, GM | 1 |
Schofield, PR | 1 |
Jones, CK | 1 |
Bubser, M | 1 |
Thompson, AD | 1 |
Dickerson, JW | 1 |
Turle-Lorenzo, N | 1 |
Amalric, M | 1 |
Blobaum, AL | 1 |
Bridges, TM | 1 |
Morrison, RD | 1 |
Jadhav, S | 1 |
Engers, DW | 1 |
Italiano, K | 1 |
Bode, J | 1 |
Daniels, JS | 1 |
Lindsley, CW | 1 |
Hopkins, CR | 1 |
Conn, PJ | 1 |
Niswender, CM | 1 |
2 other studies available for haloperidol and Anterior Horn Cell Disease
Article | Year |
---|---|
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease.
Topics: Aged; Aged, 80 and over; Brain; Cell Line, Transformed; DNA-Binding Proteins; Female; Frontotemporal | 2010 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |